Exoskeleton Training

Enables upright mobility and stepping in complete SCI; for ambulatory patients with partial injury, not superior to conventional.

Extremely limited by equipment access and patient eligibility; applicable mainly in research or SCI/stroke centers.

Very limited insurance coverage; some workers comp and select commercial beginning to cover; primarily research or cash-pay settings.

Device-specific manufacturer training; requires institutional access to exoskeleton system.

Growing interest but very limited current employer demand; primarily research hospitals and specialized centers.

High psychological value of upright posture for wheelchair users; fatigue and safety concerns limit enthusiasm.

SCI/stroke families pay cash for gait time; market is small but motivated.

Novelty and capital cost support premium per-session pricing.

Very few clinics own exoskeletons; strong differentiation.

Equipment-driven; staff can be trained, though caseload is limited.

Niche neuro population; broader consumer demand is modest.

Vendor training is short, but device cost ($75-150K) is prohibitive.

Valued in neuro rehab research labs; not a standalone promotion criterion.

Growing literature in SCI and stroke gait recovery.

Useful for neuro rehab and rehab technology coursework.

Mixed; improvements documented but long-term functional gains debated.

Rarely a posting requirement; relevant to research-active programs.

Training is fast, but academic payoff depends on institutional equipment access.

Ekso, ReWalk, Indego, and Wandercraft hire clinical specialists and trainers.

Small vendor pool but each has dedicated clinical-specialist roles.

Moderate premium for device-specialist roles at robotics vendors.

Builds genuine familiarity with robotic gait device mechanics and patient programming.

Direct bridge into medical-robotics industry roles.

High training investment relative to small vendor market.